In the study performed by Yang H et al. [60] targeting metastatic gastric cancer, it was observed that the addition of endostatin to the conventional regimen was associated with a lower degree of severity of chemotherapy-related adverse effects. The gene discussed is COL18A1; the disease is gastric cancer.